Version 1
: Received: 14 September 2023 / Approved: 20 September 2023 / Online: 21 September 2023 (11:27:47 CEST)
How to cite:
Bernaola-Paredes, W. E.; Filippetti, E. P.; Abrahao, C.; Vartanian, J. G.; Coutinho, M. C.; Montenegro-Tirado, K.; D'almeida Costa, F.; Vallejo-Rosero, K. A.; Marquez-Zambrano, J. A.; Pellizzon, A. C. A. Survival Outcomes of Patients with Head and Neck Sarcomas Submitted to Multimodal Treatment at a Single Cancer Center: A Retrospective Study. Preprints2023, 2023091472. https://doi.org/10.20944/preprints202309.1472.v1
Bernaola-Paredes, W. E.; Filippetti, E. P.; Abrahao, C.; Vartanian, J. G.; Coutinho, M. C.; Montenegro-Tirado, K.; D'almeida Costa, F.; Vallejo-Rosero, K. A.; Marquez-Zambrano, J. A.; Pellizzon, A. C. A. Survival Outcomes of Patients with Head and Neck Sarcomas Submitted to Multimodal Treatment at a Single Cancer Center: A Retrospective Study. Preprints 2023, 2023091472. https://doi.org/10.20944/preprints202309.1472.v1
Bernaola-Paredes, W. E.; Filippetti, E. P.; Abrahao, C.; Vartanian, J. G.; Coutinho, M. C.; Montenegro-Tirado, K.; D'almeida Costa, F.; Vallejo-Rosero, K. A.; Marquez-Zambrano, J. A.; Pellizzon, A. C. A. Survival Outcomes of Patients with Head and Neck Sarcomas Submitted to Multimodal Treatment at a Single Cancer Center: A Retrospective Study. Preprints2023, 2023091472. https://doi.org/10.20944/preprints202309.1472.v1
APA Style
Bernaola-Paredes, W. E., Filippetti, E. P., Abrahao, C., Vartanian, J. G., Coutinho, M. C., Montenegro-Tirado, K., D'almeida Costa, F., Vallejo-Rosero, K. A., Marquez-Zambrano, J. A., & Pellizzon, A. C. A. (2023). Survival Outcomes of Patients with Head and Neck Sarcomas Submitted to Multimodal Treatment at a Single Cancer Center: A Retrospective Study. Preprints. https://doi.org/10.20944/preprints202309.1472.v1
Chicago/Turabian Style
Bernaola-Paredes, W. E., Jose Agustin Marquez-Zambrano and Antonio Cassio Assis Pellizzon. 2023 "Survival Outcomes of Patients with Head and Neck Sarcomas Submitted to Multimodal Treatment at a Single Cancer Center: A Retrospective Study" Preprints. https://doi.org/10.20944/preprints202309.1472.v1
Abstract
BACKGROUND: Head and Neck Sarcomas (HNSs) are rare malignant tumors derived from mesenchymal cells characterized by rapid growth, local aggressive behavior, and multiple re-lapses. The Rhabdomyosarcoma (RMS) and the Osteosarcoma (OS) are the more frequent HNS. The present study aims to evaluate the clinical impact of multimodal treatment in patients diagnosed with HNS. METHODS: A retrospective analysis of medical records from patients diagnosed with HNS multimodal treated, four groups were formed: a) surgery and chemotherapy (CTX); b) surgery, CTX, and RT; c) surgery and RT; d) CTX and RT exclusively. The overall survival (OSS), disease-free survival (DFS) and progression-free survival (PFS) rates were calculated using the Kaplan-Meier test. RESULTS: Among 39 patients, 23.1% were diagnosed with RMS , 66.7% with OS and 10.3% with other subtypes of HNS. Moreover, 59% showed initial clinical staging (T1/T2) and of those 35.9% were T1. Surgery was performed in 87.2% patients, RT in 35.9% and CTX in 84.7%. RT performed showed not statistically significant clinical role regarding OSS (p=0.74), DFS (p=0.09) and PFS (p=0.90) rates independent of histological subtype. Finally, OSS (p=0.89), DFS (p=0.13) and PFS (p=0.50) rates were not statistically different for patients treated with monotherapy or multimodal therapy. CONCLUSION: RT has not showed a clinically important role referred to improve OSS, DFS and PFS rates in patients with HNS, regardless of the histological subtype of the primary tumor. Multimodal treatment could influence in survival rates and locoregional control of the disease; however, longitudinal studies such as randomized clinical trials must be conducted.
Keywords
osteosarcoma; rhabdomyosarcoma, embryonal; rhabdomyosarcoma, alveolar; radiotherapy; head and neck neoplasms
Subject
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.